Clinical Trial

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.
Trial Details
NCT Number NCT07556757
Lead Sponsor ImmunityBio, Inc.
Conditions B-ALL, Leukemia
Enrollment 10 participants
Start Date 2025-04-11
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-29